Healthcare
USPTO-FDA Study Debunks Critics and Demonstrates the Importance of Protecting IP
USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.
The IRA Has Undermined Medicare Part D
The Inflation Reduction Act creates instability in the Medicare Part D Program.
Not-So-Happy Birthday to the Inflation Reduction Act
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
New Study Shows PBMs Lower Drug Prices
A new report challenges assertions made during the committee's recent hearing on the role of pharmacy benefit managers.
The FTC Wrongly Blames PBMs for High Drug Prices
The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.
Medicare Advantage Should Not Be Disadvantaged
Taxpayers and beneficiaries should be concerned with the Biden administration’s proposed cuts to Medicare Advantage.
Misguided Use of March-In Rights Will Harm Patients
The use of march-in rights to steal intellectual property will neither lower costs nor create more access to healthcare.
North Carolinians are Being Conned by Certificate of Need Laws
North Carolina’s certificate of need laws should be repealed to increase access to quality care.
The FDA Is Adopting California’s Failed Policies on Tobacco
The FDA's proposal to ban menthol-flavored tobacco will put consumers at risk with illicit products.
The 340B Drug Discount Program Needs an Overhaul
CAGW has long been concerned with the misuse of the 340B Program.
Congress Should not Double Down on Devastating Drug Price Controls
House Democrats’ new bill on price controls will devastate future drug development and raise costs.
Another Government Report Proves That PBMs Save Taxpayers Money
PBMs lower healthcare costs and another government agency overspent because a PBM was not used.
